Crinetics Pharmaceuticals, Inc. — Director's Dealing 2019

Mar 12, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2019-03-08

Reporting Person: Struthers Richard Scott (Director, President & CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-08	Stock Option (right to buy)	$25.19	A	176250	Acquired	2029-03-07	Common Stock (176250)	Direct

Footnotes

F1: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the Vesting Commencement Date of March 8, 2019.